பிரிவு ஆஃப் அல்லாத News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from பிரிவு ஆஃப் அல்லாத. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In பிரிவு ஆஃப் அல்லாத Today - Breaking & Trending Today

Women do more unpaid work in immigrant families

May 10, 2021
Immigrant women tend to do more unpaid labor, such as housework and childcare, than native-born women in the U.S., new Cornell research has found.
A team of researchers including Francine D. Blau, the Francis Perkins Professor of Industrial and Labor Relations and professor of economics, and Lawrence M. Kahn, the Braunstein Family Professor and professor of economics, both in the ILR School, analyzed the gender division of nonmarket work, comparing immigrant and native-born men and women.
“Professors Blau and Kahn, who have been leading the study of gender and the labor market for decades, continue to break new ground with this recent award-winning study,” said Alexander Colvin, Ph.D. ’99, the Kenneth F. Kahn ’69 Dean of the ILR School. “It shows, once again, the power of their comparative work, drawing on cross-national data to deepen our understanding of the impacts of culture and gender on labor market behavior.” ....

United States , Pamela Meyerhofer , Francined Blau , Amanda Eng , Alexander Colvin , Kennethf Kahn , Matthew Comey , Lawrencem Kahn , Norwegian School Of Economics , Division Of Non , Montana State University , American Time Use , Time Use Research Award , Gender Allocation , Source Country Characteristics , Francis Perkins Professor , Labor Relations , Braunstein Family Professor , Time Use Survey , Alexander Will , Norwegian School , ஒன்றுபட்டது மாநிலங்களில் , அமண்டா எஂக் , அலெக்சாண்டர் கொல்வின் , நோர்வே பள்ளி ஆஃப் பொருளாதாரம் , பிரிவு ஆஃப் அல்லாத ,

First Drug That Protects Against Chemo-Induced Myelosuppression

First Drug That Protects Against Chemo-Induced Myelosuppression
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.

Albert Deisseroth , Division Of Non , Drug Administration , Non Malignant Hematology , Drug Evaluation , பிரிவு ஆஃப் அல்லாத , அல்லாத வீரியம் மிக்கது ஹீமாட்டாலஜி , மருந்து மதிப்பீடு ,

FDA Approves Drug to Combat Chemotherapy-Linked Bone Marrow Damage

Feb 16, 2021
Tilaciclib is first drug approved for this indication
WASHINGTON The FDA approved tilaciclib (Cosela) to reduce chemotherapy-induced bone marrow suppression in adults. Tilaciclib, which protects bone marrow cells by inhibiting cyclin-dependent kinase 4/6, is the first drug to win FDA approval for this indication.
In a prepared statement from the FDA, Albert Deisseroth, MD, PhD, supervisory medical officer in the Division of Non-Malignant Hematology in the FDA’s Center for Drug Evaluation and Research, said, “For patients with extensive-stage small cell lung cancer, protecting bone marrow function may help make their chemotherapy safer and allow them to complete their course of treatment on time and according to plan. Today’s approval of [tilaciclib] will give patients a treatment option that can reduce the occurrence of a common, harmful side effect of chemotherapy.” ....

North Carolina , United States , Research Triangle Park , Albert Deisseroth , Division Of Non , Therapeutics Inc , Non Malignant Hematology , Drug Evaluation , வடக்கு கரோலினா , ஒன்றுபட்டது மாநிலங்களில் , ஆராய்ச்சி முக்கோணம் பூங்கா , பிரிவு ஆஃப் அல்லாத , சிகிச்சை இன்க் , அல்லாத வீரியம் மிக்கது ஹீமாட்டாலஜி , மருந்து மதிப்பீடு ,

FDA approves drug to reduce frequency of chemotherapy-induced bone marrow suppression

FDA approves drug to reduce frequency of chemotherapy-induced bone marrow suppression
Today, the U.S. Food and Drug Administration approved Cosela (trilaciclib) as the first therapy in its class to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage (when the cancer has spread beyond the lungs) small cell lung cancer. Cosela may help protect bone marrow cells from damage caused by chemotherapy by inhibiting cyclin- dependent kinase 4/6, a type of enzyme.
For patients with extensive-stage small cell lung cancer, protecting bone marrow function may help make their chemotherapy safer and allow them to complete their course of treatment on time and according to plan. Today s approval of Cosela will give patients a treatment option that can reduce the occurrence of a common, harmful side effect of chemotherapy. ....

Albert Deisseroth , Emily Henderson , Division Of Non , Therapeutics Inc , Drug Administration , Supervisory Medical Officer , Non Malignant Hematology , Drug Evaluation , Breakthrough Therapy , Bone Marrow , Lung Cancer , Small Cell Lung Cancer , எமிலி ஹென்டர்சன் , பிரிவு ஆஃப் அல்லாத , சிகிச்சை இன்க் , மேற்பார்வை மருத்துவ அதிகாரி , அல்லாத வீரியம் மிக்கது ஹீமாட்டாலஜி , மருந்து மதிப்பீடு , திருப்புமுனை சிகிச்சை , எலும்பு மஜ்ஜை , நுரையீரல் புற்றுநோய் , சிறிய செல் நுரையீரல் புற்றுநோய் ,